Date: Tuesday, March 8, 2011
Signalling networks play a key role in the control of diverse cellular processes; their aberrant functioning is heavily implicated in cancer. Genomic aberrations in cancers are thought to "re-wire" the normal connectivity of signalling networks, with potentially important biological and therapeutic implications. However, we remain limited in our understanding of cancer-specific signalling. Advances in high-throughput proteomics have begun to enable quantitative studies of signalling at the network level. I will discuss statistical approaches by which to elucidate signalling network topology in cancer, including the use of sparse graphical models, Markov chain Monte Carlo algorithms and informative network priors.